KPW
STML

Kore Private Wealth’s Stemline Therapeutics, Inc. STML Stock Holding History

Kore Private Wealth’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,000
Closed -$13K – 869
2019
Q1 		$13K Buy
+1,000
New +$11.3K ﹤0.01% 578

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Kore Private Wealth's STML Position: Q2 2019 in Review

Kore Private Wealth sold out of Stemline Therapeutics, Inc. (STML) in Q2 2019, closing a stake of 1,000 shares — an estimated $13K sold.

Kore Private Wealth first reported a position in STML in Q1 2019 and held it in 1 quarter. The position peaked at $13K in Q1 2019. 96 funds tracked by Wall St. Rank hold STML as of Q2 2019.

  • Kore Private Wealth reported no remaining Stemline Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
  • Kore Private Wealth sold 1,000 Stemline Therapeutics, Inc. shares in Q2 2019, an estimated $13K.
  • Kore Private Wealth first reported a position in Stemline Therapeutics, Inc. in Q1 2019 and held it in 1 quarter.
  • Kore Private Wealth's Stemline Therapeutics, Inc. position peaked at $13K in Q1 2019.
  • 96 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2019.

Based on Kore Private Wealth's 13F filing for Q2 2019, filed 14 Aug 2019.